30026例参芪扶正注射液真实世界联合用药注册登记研究

Registration of 30026 cases of Shenqi Fuzheng injection combined with other drugs in real world

该文采取前瞻性、多中心、大样本、注册登记式研究方法,进行参芪扶正注射液上市后临床应用真实世界联合用药特征分析,了解真实世界联合用药情况。注册登记使用参芪扶正注射液患者共30 026例,合并用药化学药(57 436例次,占82.76%)多于中成药(11 962例次,占17.24%),以抗酸药物及抗溃疡病药物、营养剂、免疫增强剂等居多,根据关联规则,2种合并用药与抑制胃酸分泌和抗肿瘤密切相关;3种合并用药与抑制胃酸分泌、止吐和抗肿瘤密切相关;4种合并用药与抑制胃酸分泌、止吐、抗肿瘤、免疫增强密切相关,与说明书适应症相符,为精准治疗提供线索,也为临床合理用药奠定基础。

Prospective, multi-center, large-sample and registered design was used to analyze the drug combination features of Shen- qi Fuzheng injection in the real world clinical application, and comprehend the drug combination in the real world. A total of 30 026 patients with the use of Shenqi Fuzheng injection were registered, where the chemical drugs were used for 57 436 times （ accounting for 82.76% ） , and the Chinese patent medicines were used for 11 962 times （ accounting for 17.24% ） , mainly including anti-acid drugs and anti-ulcer drugs, nutritional agent, immune enhancement agent, etc. According to the association rules, drug combinations of 2 drugs were closely related to inhibiting gastric acid secretion and anti-tumor; drug combinations of 3 drugs were closely related to inhib- iting gastric acid secretion, antiemetic and anti tumor; drug combinations of 4 drugs were closely related to inhibiting gastric acid secre- tion, antiemetic, anti-tumor, and immune enhancement. The above results were consistent with the Instruction, providing clues for ac- curate treatment, and laying the foundation for clinical rational drug use.